Efficacy of Anti-Müllerian Hormone in Predicting the Levels of Sex Hormones and Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome Undergoing IVF-ET
Jiacheng Du and Yuping Cao*
Reproductive Medicine Center, Second People’s Hospital of Jingmen City, 39 Xiangshan Avenue, Jingmen City, Hubei Province, 448000, China
Fig. 1.
A combined diagram of the process.
Fig. 2.
Comparison of sex hormone levels of patients in two groups. a is follicle-stimulating hormone (FSH); b is luteinizing hormone (LH); c is estradiol (E2); d is progesterone (P); e is testosterone (T); f is prolactin (PRL); ** means P<0.001.
Fig. 3.
Comparison of pregnancy outcomes of patients between the two groups. a is Fertilization rate; b is Cleavage rate; c is Implantation rate; d is High quality embryo rate; e is Biochemical pregnancy rate; f is Clinical pregnancy rate; ** means P<0.001.
Fig. 4.
Comparison of Early abortion rate and pregnancy complications of patients in the two groups. a is Early abortion rate; b is Pregnancy-induced hypertension; c Gestational diabetes mellitus; **means P<0.001.
Fig. 5.
ROC curve of AMH levels predicting IVF-ET in clinical pregnancy in PCOS patients.
ROC curve analysis shows that the area below the curve is 0.783, 95% of CI is 0.586 to 0.826, the specificity is 77.52%, the sensitivity is 81.46%, the Youden index is 53.26, and the optimal cut-point is 7.149.